Bellaire, TX, United States of America

Larry W Kwak

USPTO Granted Patents = 9 

Average Co-Inventor Count = 2.0

ph-index = 3

Forward Citations = 63(Granted Patents)


Location History:

  • Frederick, MD (US) (2003 - 2011)
  • Houston, TX (US) (2013)
  • Bellaire, TX (US) (2011 - 2014)

Company Filing History:


Years Active: 2003-2014

Loading Chart...
9 patents (USPTO):Explore Patents

Title: Innovations of Larry W. Kwak

Introduction

Larry W. Kwak is a prominent inventor based in Bellaire, TX (US). He has made significant contributions to the field of immunology, particularly in the development of vaccines aimed at treating cancer and viral infections. With a total of 9 patents, his work has the potential to impact the lives of many patients.

Latest Patents

One of his latest patents involves defensin-antigen fusion proteins. This invention relates to a vaccine designed to increase the immunogenicity of tumor antigens, thereby facilitating cancer treatment. Additionally, it addresses the enhancement of viral antigens' immunogenicity, which is crucial for treating viral infections, including HIV. The invention provides a fusion protein that combines a defensin with either a tumor antigen or a viral antigen. This fusion protein can be administered as either a protein or nucleic acid vaccine, eliciting an immune response effective in treating cancer or preventing viral infections.

Career Highlights

Larry W. Kwak is affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. His work at this esteemed institution has allowed him to focus on groundbreaking research in immunology and vaccine development.

Collaborations

Some of his notable coworkers include Bira Arya and Arya Biragyn. Their collaborative efforts contribute to the advancement of research in the field of immunology.

Conclusion

Larry W. Kwak's innovative work in vaccine development showcases his commitment to improving healthcare outcomes. His contributions to the field of immunology are significant and continue to pave the way for future advancements in cancer and viral infection treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…